Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Azusa, California, United States
Costa Mesa, California, United States
Lynwood, California, United States
Riverside, California, United States
San Diego, California, United States
Denver, Colorado, United States
Macon, Georgia, United States
Shreveport, Louisiana, United States
Brooklyn Center, Minnesota, United States
Philadelphia, Pennsylvania, United States
Start Date
February 20, 2011
Primary Completion Date
July 1, 2011
Completion Date
August 24, 2011
Last Updated
April 13, 2017
87
ACTUAL participants
Etelcalcetide
DRUG
Placebo
DRUG
Lead Sponsor
KAI Pharmaceuticals
NCT03633708
NCT04922892
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04064827